CTLA4 and neoplasm: Tremelimumab is a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-targeted humanized IgG2 monoclonal antibody, which inhibits tumor growth by preventing the interaction between CTLA-4 and B7s and thereby allowing T-cell activation [168].